<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557945</url>
  </required_header>
  <id_info>
    <org_study_id>7165R</org_study_id>
    <nct_id>NCT02557945</nct_id>
  </id_info>
  <brief_title>Gabapentin in Patients at Clinical Risk for Psychosis</brief_title>
  <official_title>Gabapentin in Patients at Clinical Risk for Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effects of the drug gabapentin on brain function
      thought to be important in the development of schizophrenia. Researchers think that treating
      a brain region with gabapentin (the hippocampus) may reduce the risk for developing
      schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left CA1 Cerebral Blood Volume (CBV) (MRI measure)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in left CA1 CBV (MRI measure) in patients who receive active drug vs. placebo, after 6 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in positive, negative, disorganization, and general symptoms over time as measured by the Structured Interview for Psychosis-Risk Syndromes (SIPS)/the Scale of Psychosis-Risk Symptoms (SOPS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Exploratory analyses will be conducted examining the effects of gabapentin on changes in Positive symptoms (P scores), negative symptoms (N scores) and general symptoms (G scores) and disorganization symptoms (D scores) compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function (hippocampal-dependent verbal memory) as measured by the California Verbal Learning Test-Second Edition (CLVT-II)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Exploratory analyses will be conducted on changes between gabapentin and placebo groups on the California Verbal Learning Test-Second Edition (CLVT-II) measures (e.g., Learning slope)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Clinical High Risk for Psychosis</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin 3600mg PO daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo PO daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. COPE patient between age of 18-30

          2. Capacity to give informed consent

          3. Currently using a reliable method of birth control (female) (condom plus spermicide,
             diaphragm plus spermicide, IUD, birth control pills, norplant, vasctomy in partner)

        Exclusion Criteria:

          1. Metal implants in body or a history of metal working, or more than one past MRI scan
             with gadolinium

          2. Lifetime diagnosis of asthmatic symptoms within the past 3 years or known sensitivity
             to contrast agents

          3. Lifetime diagnosis of renal failure/disease

          4. Acute neurological, neuroendocrine,or medical disorder including renal insufficiency

          5. Lifetime diagnosis of hypertension or diabetes

          6. Intelligence Quotient (IQ) &lt; 70

          7. Acute risk for suicide and/or violence

          8. Pregnant, lactating

          9. Current abuse of substances (alcohol, cocaine, stimulants, cannabis, opiates, sedative
             hypnotics)

         10. Current use or anticipated need for antipsychotics or mood stabilizers (all
             antipsychotics, also Depakote, lithium, lamotrigine, pregabalin or any med with a
             mechanism of action like gabapentin)

         11. The Clinical Global Impressions Scale (CGI)-improvement score during study equal to or
             greater than 6
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ragy Girgis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYSPI/Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Brucato, PhD</last_name>
    <phone>646-774-5232</phone>
  </overall_contact>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Brucato, PhD</last_name>
      <phone>646-774-5232</phone>
      <email>gb2428@columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

